We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-8.93%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
-$295M
Cap. Flow
-$42.8M
Cap. Flow %
-3.19%
Top 10 Hldgs %
61.63%
Holding
43
New
8
Increased
12
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$55.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$53.4M
3
CYTK icon
Cytokinetics
CYTK
+$43.8M
4
UTHR icon
United Therapeutics
UTHR
+$41M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$40.2M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$134M
2
ALGN icon
Align Technology
ALGN
+$75.1M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$63.2M
4
EXAS
Exact Sciences
EXAS
+$53.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$41.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
1
Karyopharm Therapeutics
KPTI
$159M
$138M 10.27%
478,713
+70,217
+17% +$19.4M
UTHR icon
2
United Therapeutics
UTHR
$26.2B
$128M 9.53%
1,350,360
+431,097
+47% +$41M
AUPH icon
3
Aurinia Pharmaceuticals
AUPH
$1.93B
$100M 7.47%
6,909,374
+283,703
+4% +$5M
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
$92.3M 6.87%
2,297,779
+396,112
+21% +$16.8M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$80.5M 6%
823,165
+467,020
+131% +$53.4M
KDMN
6
DELISTED
Kadmon Holdings, Inc.
KDMN
$65.4M 4.87%
15,608,948
-33,116
-0.2% -$143K
OMER icon
7
Omeros
OMER
$863M
$59.9M 4.46%
4,479,872
+1,284,076
+40% +$17.1M
CDNA icon
8
CareDx
CDNA
$1.97B
$58.1M 4.33%
2,660,716
+538,740
+25% +$12.1M
AKBA icon
9
Akebia Therapeutics
AKBA
$362M
$54M 4.02%
+7,121,283
New +$55.4M
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$51.3M 3.82%
3,304,918
-1,001,657
-23% -$21.5M
QURE icon
11
uniQure
QURE
$2.93B
$49M 3.65%
1,032,636
+103,600
+11% +$5.95M
ASMB icon
12
Assembly Biosciences
ASMB
$516M
$47.1M 3.51%
264,628
+108,095
+69% +$23.2M
PRNB
13
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$41M 3.05%
+689,718
New +$40.2M
CYTK icon
14
Cytokinetics
CYTK
$10.9B
$40.5M 3.01%
+3,432,232
New +$43.8M
AXGN icon
15
Axogen
AXGN
$2.2B
$37.1M 2.76%
3,566,054
+579,668
+19% +$7.38M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$6.1B
$34.7M 2.58%
+2,240,779
New +$35.1M
APTO
17
DELISTED
Aptose Biosciences, Inc.
APTO
$34.4M 2.56%
12,881
+2,276
+21% +$6.79M
TVTX icon
18
Travere Therapeutics
TVTX
$5.33B
$33.8M 2.51%
2,314,421
– –
CHRS icon
19
Coherus Oncology
CHRS
$227M
$32.8M 2.44%
+2,020,002
New +$37.3M
KRYS icon
20
Krystal Biotech
KRYS
$10.8B
$28.3M 2.11%
654,586
+450,798
+221% +$23.6M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$25.4M 1.89%
1,654,600
-320,400
-16% -$6.96M
XENE icon
22
Xenon Pharmaceuticals
XENE
$6.2B
$22.4M 1.67%
+1,979,669
New +$28.2M
LMNL
23
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
$22M 1.64%
328,731
– –
BLU
24
DELISTED
BELLUS Health Inc.
BLU
$15.9M 1.19%
+1,597,503
New +$14.2M
OXFD
25
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$11.5M 0.86%
1,244,460
-1,119,264
-47% -$15.6M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Consonance Capital Management held 43 positions worth $1.34B, down 18% from $1.64B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Consonance Capital Management withdrew a net $42.8M in Q1 2020, closing 12 positions and reducing 9 holdings. Its most notable exit was Arqule Inc, an estimated $134M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Akebia Therapeutics worth $54M.

  • Consonance Capital Management's largest Q1 2020 buy was Akebia Therapeutics: 7,121,283 shares worth $54M.
  • Consonance Capital Management added most to Sarepta Therapeutics in Q1 2020, an estimated $53.4M increase.
  • Consonance Capital Management's biggest Q1 2020 reduction was Epizyme, Inc, cutting an estimated $21.5M.
  • Consonance Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $134M.
  • Consonance Capital Management's ten largest holdings make up 62% of its $1.34B portfolio in Q1 2020.
  • Consonance Capital Management opened 8 new positions and closed 12 in Q1 2020.
  • Consonance Capital Management's portfolio value fell 18% quarter-over-quarter to $1.34B.

Based on Consonance Capital Management's 13F filing for Q1 2020, filed 15 May 2020.